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The  New  Zealand  black  (NZB)  mouse  strain  and  its  F1  hybrid  with  the  New 
Zealand  white  (NZW)  strain,  B/WF1,  are  a  widely  studied  model  of  human 
diseases  of  unknown  etiology.  These  include  idiopathic  glomerulonephritis, 
systemic  lupus  erythematosus,  related  connective  tissue  and  autoimmune 
diseases,  and malignant  lymphoma  (see reviews  1-3). 
Several studies have implicated murine leukemia virus  (MuLV) 1 in the  pathogenesis of 
the spontaneous diseases of New Zealand mice (4-8}. MuLV-related antigens appear early 
in the life of NZB mice, and antibodies to the endogenous virus in later life, accompanied 
by the  manifestation of immune  complex glomerulonephritis (5). These antibodies were 
found  by  immunoelectron  microscopy to  react  with  viral envelope components  (9-11}. 
B/WF1 hybrid mice show an earlier production of MuLV-related antigens and antibody as 
compared to NZB  mice,  correlating with the  earlier onset of proteinuria and  mortality 
from  lupus-like  glomerulonephritis.  MuLV-related  antigens  and  antibody  have  been 
demonstrated  in  the  eluates  of  nephritic  kidneys,  and  the  antigens  located  in  the 
glomerular lesions of NZB and B/WF1 mice by the immunofiuorescence method (5, 6). As 
the antiserum used in the previous studies contained antibodies to several MuLV-related 
antigens,  it is not known  whether  one  or several of the viral proteins is involved in the 
glomerular disease. 
In the  present report we describe the  use  of monospecific antisera for the analysis of 
specific viral proteins that could be of significance in the pathogenesis of glomerulonephri- 
tis in these mice. One of the proteins is the major internal structural component of MuLV 
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with a  mol wt of 30,000  (p30).  The other is the major glycoprotein  constituent of" MuLV 
which recently was  purified and found to be composed  of two glycopeptides  of apparent 
mol wt of 69,000 and 71,000 (gp69/71)  (12,  13) and has been shown by virus neutralization 
and immunofluorescence studies with anti-MuLV  gp69/71 serum to be a component of the 
virion envelope  (reference  14 and footnote 2). 
We  now  present  evidence  which  shows  that  New  Zealand  mice  contain  an 
extremely  high  tissue  and  serum  concentration  of  gp69/71  and  that  the  virion 
envelope  glycoprotein  is  selectively  deposited  in  the  glomerular  lesions  as 
compared  to p30.  These  findings  suggest  that  the  expression  of this  specific viral 
envelope  protein  is related  to the  pathogenesis  of immune  complex  glomerulone- 
phritis  of New  Zealand  mice. 
Materials  and Methods 
Mice.  NZB, NZW, and their F1 hybrid mice, B/WF~ and W/BF~ were from our colonies. AKR/J 
and C57BL/6J mice were purchased from" Jackson Laboratories, Bar Harbor, Maine. These mice were 
maintained under a  specific pathogen-free environment. 
Purification  of Viral Proteins.  The major structural protein of Rauscher MuLV  (p30) and the 
membrane glycopeptides of Rauscher  MuLV  (gp69/71)  were purified by phosphocellulose column 
chromatography and Sephadex gel filtration, as previously described (12). 
Antisera.  Goat  anti-Rauscher  MuLV  p30  (anti-p30)  and  goat  anti-Rauscher  MuLV  gp69/71 
(anti-gp69/71) sera were obtained from goats immunized by repeated injections of purified proteins in 
Freund's adjuvant. The monospecific anti-p30 serum chiefly contains antibodies directed against the 
group-specific and interspecies determinants of p30 protein with a  smaller fraction of type-specific 
antibodies  (13).  The  anti-gp69/71  serum  chiefly  contains  type-specific  and  group-specific  and  a 
smaller traction of interspecies antibodies (13).  (W/Fu  ×  BN)F~  anti-W/Fu(C58NT)D(anti-NTD) 
serum produced in (W/Fu ×  BN)FI rats bearing transplantable leukemia (C58NT)D induced in the 
W/Fu  rat  by  wild-type  MuLV  was  kindly  supplied  by  Doctors  E.  Stockert  and  L.  J.  Old 
(Sloan-Kettering Institute for  Cancer Research,  New  York).  Antibody specificities in this serum, 
except  natural heteroantibody, are  directed to antigens related to MuLV including the structural 
proteins of MuLV, a viral envelope component (9-11) and the group and interspecies antigens Of the 
p30 protein (15  19),  GCSA (a)  and (b) (15),  and GIX (20,  21). As the immunoglobulins of these sera 
reacted  with normal cellular components of mouse tissues,  the sera were absorbed with C57BL/6J 
spleen and thymus cells in order to remove these reactants, as described elsewhere (22). 
Radioimmunoassay.  Assay of viral protein was carried out by radioimmunoassay as described by 
Hunter (23). The reaction mixture contained the following: 0.005 ml normal rabbit serum, 0.01  ml 
125I-labeled  virus protein (1 or 2 ng of' protein containing 104 to 10 ~ counts/min/ng), either 0.15 ml of 
cell extract or 0.01 ml of purified virus or viral protein as competing proteins, and as the final addition 
0.01  ml  of rabbit  anti-Theilen feline  leukemia  virus serum  diluted  in  TEN-buffer  containing 20 
mg/ml  of  crystalline  bovine  serum  albumin  and  added  at  a  concentration  which  precipitated 
approximately 50% of the 12~I-labeled  antigen. The competing proteins were diluted in TEN-buffer 
(20 mM Tris-hydrochloride, pH 7.6,  1 mM EDTA,  and 100 mM NaCt) and Triton X-100 (0.2% final 
concentration), and contained 20 mg/ml of carrier crystalline serum albumin for purified virus or viral 
proteins  and  2  mg/ml  for  cell  extracts.  The  total  vol  of the  assay  was  adjusted  to  0.2  ml  with 
TEN-buffer  containing 0.2%  Triton  X-100  and  2  mg/ml  crystalline  bovine serum  albumin.  The 
reaction mixture was incubated at 37°C for 15-18 h, after which 0.04 ml of goat antirabbit IgG serum 
was  added.  Incubation  was  continued  at  37°C  for  an  additional  2  h  and  followed  by  overnight 
incubation  at  2-4°C.  Cold  TEN-buffer  (0.5  ml)  was  added  and  the  precipitate  was  collected  by 
2 Ikeda, H., T. Pincus, T. Yoshiki, M. Strand, J. T. August, E. A. Boyse, and R. C. Mellors. 1974. 
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centrifugation at 4°C. The pellet was washed twice with 0.5 ml of TEN-buffer and the l~SI-labeled 
antigen present in the precipitate was measured in a gamma counter. 
Perfusion of Mouse Kidney.  Mice were anesthesized by ether and the kidneys were perfused in 
situ with cold Earle's balanced salt solution until macroscopically free of blood. Two or three blocks of 
kidney tissues were rapidly frozen at  -70°C for immunofluorescence study, and the remainder was 
fixed with Vandegrift's fixative for light microscopic examination. 
Kidney  Eluate.  Acid-buffer (pH 3.2)  eluate after an elution step with deoxyribonuclease was 
prepared as previously described (6,  24). 
Immunofluorescence Analysis of Kidney Section.  MuLV-related antigens in the kidneys were 
located  by  treating  frozen sections of perfused  kidneys  with  either  anti-p30  or  anti-gp69/71  or 
anti-NTD sera, followed by fluoresceinated antibody to goat and rat gamma globulins, respectively. 
Fiuoresceinated  antibodies  were  absorbed  with  mouse  gamma  globulins  in  order  to  remove 
cross-reacting antibodies to mouse gamma globulins. Autologous mouse gamma globulins located in 
the kidneys were examined directly by treating the sections with fluoresceinated goat antimouse 
gamma globulin antibody that had been absorbed with mouse liver powder to remove nonspecific 
fluorescence.  The  specificity  of  fluorescence  reaction  of  kidneys  was  tested  by  absorbing  the 
antiserum with viral antigens as described previously (25). 
Immunofluorescence Analysis of Fixed Cells.  The preparation of acetone-fixed cells on slides and 
the immunofluorescence analysis of acetone-fixed cells were described elsewhere {reference 26 and 
footnote  2).  The  standard  target  cells  were  transplanted  leukemia  ECG2  originally  induced  in 
C57BL/6J mouse by passage A Gross virus (27). The immunofluorescence  absorption test was carried 
out as follows: 20 tLl of antiserum two dilutions below the fluorescence end point and the same volume 
of serially diluted antigen were mixed and incubated overnight at 4°C. The residual antibody activity 
was tested on acetone-fixed E~G2 cells by immunofluorescence test. The result of absorption was 
expressed as the maximal dilution of antigen capable of removing antibody activity from the given 
dilution of the antiserum. 
Elution of Kidney Sections.  Perfused kidney sections were incubated in 0.12  M  glycine buffer 
(pH 3.0) for 45 rain at 37°C with constant shaking in order to elute bound immunoglobulins from the 
glomeruli as described by Oldstone et al.  (28). 
Immunodiffusion  Test.  Ouchterlony plates prepared with 0.5%  agarose in phosphate-buffered 
saline, pH 7.2,  containing 0.03% sodium azide were incubated at room temperature in a humidified 
chamber.  Optimal  precipitation  occurred  within  24  h.  The  pooled  serum  used  as  antigen  was 
concentrated to one-fifth of original volume by Minicon-B (Amicon Corp., Scientific System Div., 
Lexington, Mass.) at 4°C. 
Histology.  Hematoxylin and eosin, and periodic acid-Schiff staining were carried out as usual. 
The histologic grading of nephritis was previously described (29). 
Urinalysis.  Test for proteinuria was performed as previously described (29). 2+ positive reactions 
were graded as significant proteinuria, and 3+  as highly significant proteinuria. 
Results 
Tissue  Concentration  of Viral Proteins.  The  concentration of viral p30 and 
gp69/71  in  extracts  of  spleens  of  NZB,  NZW,  B/WF1,  and  W/BFI  mice  was 
measured  by  radioimmunoassay.  A  heterologous assay  system  with  antifeline 
leukemia  virus  serum  and  murine  virus  l~SI-labeled  protein  as  antigen  was 
utilized  so as  to  restrict  antibody binding specifically  to  common  interspecies 
antigenic determinants.  This choice of a heterologous system  was essential to a 
quantitative  assay as  previous experiments  have  shown that the  concentration 
and antibody affinity of the interspecies antigens were indistinguishable among 
the  several  different  murine  viruses  tested,  Rauscher,  Friend,  Moloney  and 
Gross,  and  AKR.  This  was  in  contrast  to  the  results  obtained  by  use  of  a 
homologous  assay  system  of  antimurine  virus  serum  and  the  murine  virus 
proteins,  in  which case  the p30 or gp69/71  proteins of other viruses would not 1014  MULV  PROTEIN  AND  IMMUNE  COMPLEX  GLOMERULONEPHRITIS 
compete for binding of type-specific antigens of the labeled  protein (13). 
Extremely high  concentrations of gp69/71  were  detected,  this  viral  envelope 
protein  being  present  in  large  excess  over  the  viral  p30  internal  protein  and 
comprising almost 0.1% of the  total protein of the spleen extract  (Table  I).  By 
comparison,  a  high  incidence  leukemia  strain  AKR  contained  135  ng  p30/mg 
spleen  protein  and  50  ng  gp69/71/mg  spleen  protein,  and  a  low  incidence 
leukemia strain C57BL/6J contained even lower concentrations of these proteins, 
17 and  22 ng/mg spleen protein,  p30 and gp69/71, respectively. In other studies 
TABLE  I 
p30 and gp69/71  in Spleens of New Zealand Mice 
Strain  Age  p30  gp69/71 
NZB 
ng viralprotein/mg total 
mo  spleen protein* 
9  205  700 
10  200  825 
ll  365  875 
NZW  5  66  660 
5  83  675 
6  100  665 
B/WF1  3  100  780 
3  100  660 
3  134  700 
W/BF,  2  77  675 
3  118  760 
3  100  770 
AKR$  2  135  50 
C57BL/65  2  17  22 
Radioimmunoassay was performed as described in the Materials and Methods. 
* Values represent single determinations of individual spleens. 
SMice were obtained by the courtesy of Dr. F. Lilly (Albert Einstein College of Medi- 
cine, New York). 
(30), these proteins in spleens of a large number of other mouse strains have been 
measured  by  the  same  assay  and  in  no  case  did  the  concentrations of viral 
proteins approach those of the  New  Zealand  mice,  particularly in  the  case  of 
gp69/71. 
The relative concentration of viral p30 and gp69/71 in the pooled sera of NZB, 
NZW, B/WF1, and W/BF1 was measured semiquantitatively by immunofluores- 
cence absorption test (Table II). A large amount of gp69/71 was demonstrated in 
the serum of NZB, NZW, and their F1 hybrid mice at various ages. In contrast, 
p30  protein  was  not  demonstrated  by  the  assay  method  employed.  The 
concentrations of the proteins were also measured by radioimmunoassay. There 
was  a  1,000-fold greater concentration of gp69/71,  25 #g/ml,  than  of p30,  0.02 
ttg/ml, in the serum of each of these mice. The identity of these proteins was also T.  YOSHIKI,  R.  C.  MELLORS,  M.  STRAND,  AND J.  T.  AUGUST 
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Strain  Age 
Antigen titer* 
p30  gp69/71 
NZB 
NZW 
B/WF, 
W/BF, 
AKR/J 
C57BL/6J 
mo 
3-5  0  32 
6-12  0  32 
13-19  0  32 
>20  0  16 
5-8  0  32 
10-12  0  32 
13-15  0  32 
16-24  0  32 
2-4  0  32 
5-7  0  16 
8-10  0  32 
1-2  0  32 
4  0  16 
5-6  0  32 
7-9  0  16 
6  2  4 
3  0  0 
7-8  0  0 
>12  0  0 
* Antigen titer was determined by immunofluorescence  absorption test of anti-p30 and 
anti-gp69/71 as described in the Materials and Methods. The residual antibody activ- 
ity was tested on acetone-fixed E~G2 cells. 
determined  by  Ouchterlony tests.  A  precipitin  line  of identity was  observed 
between concentrated NZB sera  and  sonicated Rauscher MuLV against anti° 
gp69/71,  with  faint  spur  formation  indicating  the  presence  of  type-specific 
antibodies  in  the  antiserum  reaction  with  Rauscher  MuLV.  The  precipitin 
reaction against anti-gp69/71 was also observed with concentrated sera of B/WF 1, 
NZW,  and AKR/J. The  precipitin reaction against anti-p30 was not detected 
even after the same sera had been treated with ether so as to disrupt any virus 
particles. 
Immunofluorescence  Analysis of Kidney Sections.  Frozen sections of kidneys 
of  NZB,  B/WF1,  NZW,  C57BL/6J,  and  AKR/J  mice  at  various  ages  were 
analyzed by immunofluorescence for the location of viral envelope glycoprotein, 
gp69/71  and internal protein, p30.  The bound immunoglobulins located in the 
kidneys were simultaneously studied by use of fluoresceinated goat antibody for 
the presence of mouse immunoglobulins. 
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mainly in the mesangia and less in the peripheral capillary loops and cytoplasm 
of some tubules (Figs. 1 and 2). The glomerular deposition of this protein in mice 
of  different  ages  usually  appeared  to  coincide  with  the  manifestation  of 
significant proteinuria and glomerulonephritis.  The p30 protein was not detected 
in the kidneys over the age range studied. 
With B/WF, mice, gp69/71 was found heavily deposited in a granular pattern, 
mainly in the peripheral capillary loops and less in the mesangia (Figs. 3 and 4). 
The  distribution  of gp69:71  was similar  to that  of bound immunoglobulins  and 
was related  to the  severity of lupus-like  glomerulonephritis  (Fig.  5).  A  B/WF1 
mouse also revealed a  granular  deposition of both gp69/71 and bound immuno- 
globulins in the walls of vessels affected by an acute necrotizing vasculitis (Fig. 
6).  There  was no specific deposition  of p30 in  the  kidneys  over the  age range 
studied. 
With  NZW and  C57BL/6J mice,  gp69/71  and  bound  immunoglobulins  were 
found to be deposited in the glomeruli,  mainly in the mesangia  and  increasing 
with age (Figs. 7 and 8). The p30 protein was not demonstrated in the kidneys. A 
minimal  histologic grade of nephritis  was present in many of these mice. 
With  aging  AKR/J  mice,  gp69/71  was present  mainly  in  the  mesangia  with 
diffuse pattern  (figure  not  presented).  Bound  immunoglobulins  were detected 
focally in the mesangia,  sometimes along capillary walls. A trace amount of p30 
was detected in the glomeruli of both young and aging mice. A minimal grade of 
nephritis  was noted in aging mice. 
The  immunofluorescence  analysis  of kidney  sections  by anti-NTD  revealed 
that the fluorescence pattern of MuLV antigens detected by anti-NTD was quite 
similar to that detected by anti-gp69/71  serum,  in keeping with the finding that 
the predominant viral protein in the tissues is gp69/71 (Fig. 9). The mice studied, 
the proteinuria status, and the extent of deposition of MuLV antigens and bound 
immunoglobulins  are summarized  in Table III. 
Specificity  of  Immunofluorescence  Reaction.  The  specificity  of  immuno- 
fluorescence reactions  on the  kidney sections was tested by absorbing the anti° 
gp69/71  with  various  viral  antigens  and  mouse gamma  globulins as  previously 
described (25).  The residual antibody activity was tested on the kidney sections 
of NZB,  B/WF1,  and  C57BL/6J mice, respectively. No immunofluorescence re- 
action  was  observed after  absorption  with  either  sonicated  ECG2  and  AKR/J 
leukemic thymus, known to contain high concentrations of virus or viral proteins, 
or  intact  Rauscher  MuLV  suspension.  Sonicated  thymus of C57BL/6J  mice,  a 
low-leukemia low-virus strain,  intact feline leukemia virus suspension, and mouse 
gamma globulins did not absorb out the antibody activity from anti-gp69/71 (Fig. 
10). The results were fully concordant for NZB, B/WFi, and C57BL/6J mice. It 
was concluded that  the  immunofluorescence reaction  with anti-gp69/71  specifi- 
cally involves the group-specific antibodies of the anti-Rauscher MuLV gp69/71 
reacting with the  related  determinants  of gp69/71  produced by the endogenous 
viruses of the other strains of mice tested. 
Elution of Bound Immunoglobulins  and  Viral Antigens.  Sections of kidneys 
were eluted with 0.12 M  glycine buffer followed by immunofluorescence analysis 
which  showed removal of both  bound  immunoglobulins  and  gp69/71  from  the 
glomeruli  of  each  of  the  positive  kidneys  except  for  strain  AKR/J.  The Fro.  1 and FIG. 2.  Immunofluorescence  photomicrographs of frozen section of perfused kid- 
neys of mice. (1) NZB (12 mo, O. gp69/71 located in mesangia and wall of peripheral capillary 
loops of two glomeruli and also in some tubules,  x  500. (2) Bound immunoglobulins located in 
mesangia and wall of peripheral capillary loops of two glomeruli in nearby section, x  500. 
1017 FIG.  3  and FIG.  4.  Immunofluorescence photomicrographs of frozen sections of perfused kid- 
neys of mice. B/WF~ (12 mo, ~). gp69/71 heavily located in wall of peripheral capillary loops and 
to a  lesser extent in mesangia of two glomeruli and also in some tubules.  ×  500. 
1018 FIG. 5.  Immunofluorescence photomicrographs of frozen sections of perfused kidneys of mice. 
(a) B/WFI (12 mo, ~). gp69/71  located in a glomerulus. (b) Bound immunoglobulins located in 
the same gIomerulus in nearby section. Note that the glomerular distribution of both gp69/71 
and bound immunoglobulins is strikingly similar although the fluorescence pattern is different 
from one to the other,  x  500. 
Fro. 6.  Immunofluorescence photomicrographs of frozen sections of perfused kidneys of mice. 
{a) B/WF1 (14 mo, ~). gp69/71  located in the wall of a vessel affected by an acute necrotizing 
vasculitis, x  415. (b) Bound immunoglobulins located in the same affected vessel in nearby sec- 
tion. Note similar distribution of gp69/71  and bound immunoglobulins. ×  415. 
1019 Fro. 7.  Immunofluorescence photomicrographs of frozen sections of perfhsed kidneys of mice. 
(a) NZW (10 mo, 2). gp69/71  located in mesangium and capillary wall of a glomerulus. ×  500. 
(b) Bound immunoglobulins located in mesangium and sparsely in wall of peripheral capillary 
loops of a glomerulus in nearby section. ×  500. 
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distribution of gp69/71 in the tubules was not changed. The results indicate that 
gp69/71  located  in  the  glomeruli  of  these  mice  was  deposited  with  bound 
immunoglobulins,  whereas  that  in  the  tubules  was  neither  associated  with 
immunoglobulins nor eluted from the tubular cells. With AKR/J kidney sections, 
the detection of p30 and gp69/71 in the glomeruli was enhanced after elution of 
bound  immunoglobulins,  suggesting  that  in  this  strain  the  gp69/71  and  p30 
proteins were mainly firmly fixed to the glomeruli. 
Demonstration  of gp69/71 in the Kidney Eluate.  The presence of gp69/71 in 
the  kidney eluates was  demonstrated by absorption  of anti-gp69/71  using the 
kidney  eluates  as  antigen  source,  and  testing  the  residual  antibody  activity 
against acetone-fixed E3G2 cells as described in the Materials and Methods. The 
relative amount of gp69/71  in the  kidney eluate was  related to the severity of 
glomerulonephritis. The gp69/71  antigen titer  (starting dilution  1:4),  strain  or 
hybrid,  and  age  were  as  follows:  <4,  C57BL/6J (8-12  mo),  NZW (11-18  mo), 
AKR (6 mo); 4, B/WF1 (3-4 mo); 8, NZB (9-22 mo); 16, B/WF1 (5-8 mo). These 
results  are  consistent with  the  observed distribution  of gp69/71  in  the  kidney 
sections and also with the disappearance from the glomeruli of both gp69/71 and 
bound immunoglobulins after glycine buffer elution. 
Discussion 
The main  conclusions that  can be drawn from these experiments are that the 
tissues and serum of NZB, NZW, and their F1 hybrid mice contain a remarkably 
high concentration of the viral envelope glycoprotein, gp69/71, more than 10-fold 
greater than that found in the high incidence leukemia strain AKR, 30- to 40-fold 
greater  than  in  the  low  incidence  leukemia  strain  C57BL/6,  and  1,000-fold 
greater than in BALB mice (30); and that the gp69/71 is deposited, apparently as 
an immune complex, in the diseased kidneys of these mice and in much greater 
concentration than the p30 major structural protein of the virus.  While minor 
viral proteins not analysed in this study may also prove to be of pathogenetic 
importance, the present investigation suggests that the pathogenesis of immune 
complex glomerulonephritis in mice is in some manner related specifically to the 
expression of the  glycoprotein and  the  host  immune response to this  protein. 
Several genes influence the relative expression of virus and viral proteins, Gv-1, 
H-2, or Fv-1 (see review, 31), and one or more of these genes may be abnormally 
expressed in New Zealand mice (30). Aging New Zealand mice are deficient in 
the T-cell-mediated immune response (32-38); it is possible that this abnormal- 
ity is related to the extremely high concentration of gp69/71 in the tissues and 
serum of these mice (30,  39). 
FIG. 8.  Immunofluorescence  photomicrographs  of frozen  sections  of perfused kidneys  of mice. 
(a) C57BL/6J (8 mo, ~). gp69/71 located in mesangium of a glomerulus. × 500. (b) Bound im- 
munoglobulins located in mesangium of a glomerulus in nearby section. × 500. 
FIG. 9.  Immunofluorescence  photomicrographs  of frozen  sections of perfused kidneys  of mice. 
B/WF~ (12 mo, ~). MuLV-related  antigens located in a glomerulus demonstrated  by anti-NTD. 
Note that the glomerular  distribution and fluorescence  pattern is similar to that of gp69/71 (see 
Figs. 3-5 a). × 500. 1022  MULV  PROTEIN  AND  IMMUNE  COMPLEX  GLOMERULONEPHRITIS 
TABLE III 
Mice  Studied,  Proteinuria  Status,  and Findings  in Kidneys 
No. of  Protein- 
Strain  Age  mice  uria  Nephritis*  Host IgG$  p305  gp69/71  $ 
NZB 
mo 
3  3  -  +  - 
6  3  -/+  +  +  -  -/+ 
8  1  2+  2+  2+  -  2+ 
9  2  2+/3+  2+/3+  2+/3+  -  2+/3+ 
12  1  3+  2+  3+  3+ 
13  3  3+  3+  2+/3+  -  2+/3+ 
13  2  3+  3+  3+  -  /+ 
16  1  3+  3+  3+  -  2+ 
B/WF1  2  4  -/+  -  -  - 
8  3  3+  3+  3+  -  3+ 
11  3  3+  2+/3+  3+  -  2+/3+ 
12  1  3+  3+  3+  -  3+ 
14  1  3+  3+  3+  -  3+ 
NZW  3  3  .... /tr. 
10  3  -/+  /+  +  -  /+ 
C57BL/6J  2  3  +  -  - 
8  3  /+  +  +  + 
AKR/J  2  3  +  -/tr.  /tr.  -/tr. 
6  3  -/+  +  +  -/tr.  + 
*The histologie grading of nephritis was maximal (3+),  intermediate (2+),  minimal (+), and nega- 
tive (-). 
:~The degree of fluorescence staining for host IgG, p30, and gp69/71 in the glomeruli was diffuse in- 
tense (3+), focal intense (2+),  trace (tr.), and negative (-). 
A  clearly  important  factor  in  the  pathogenesis  of  immune  complex-type 
glomerulonephritis  (40,  41)  is  the  quantity  and  quality  of  the  antibodies 
produced in the host immune response to specific antigenic stimulation. It is now 
evident that  the  immune  response  to  a  specific  antigen  is  a  complex  process 
which  involves  host  genetic  controls  at  several  levels.  In  mice,  Ir  (immune 
response)  -1 genes linked to the K  end of H-2  locus are known to determine the 
extent of antibody response to  certain antigens (42,  43).  Sato  et  al.  (44)  have 
demonstrated that the immune response to MuLV envelope antigen is controlled 
by the Rgv-1 locus (31, 45) which is located at the K  region of H-2  and functions 
as an immune response gene. It appears that the immune response of NZB and 
NZW mice to the gp69/71 differs. Both strains have similar high tissue and serum 
concentration of this protein, yet the NZW strain develops a  minimal histologic 
grade of nephritis compared to NZB and their F1 hybrid mice. As antibodies to 
viral  envelope  components  of  MuLV  have  been  described  (9-11,  46,  47)  and 
endogenous mouse  antibodies specifically directed  against  gp69/71  have  been 
detected  (M.  Strand  and  J.  T.  August,  unpublished  data),  experiments  to 
measure the amount of antibodies to gp69/71 in the kidney eluates and serum of FI6.  10. Immunofluorescence photomicrographs of frozen sections of perfused kidneys of mice. 
B/WF~ (11 mo, 3). Specificity of immunofluorescence reaction by anti-gp69/71. (a) Anti-gp69/ 
71 absorbed with sonicated C57BL/6J thymus. (b) Anti-gp69/71 absorbed with intact Rauscher 
MuLV suspension, (c)  Anti-gp69/71 absorbed with sonicated E3G2 cells. (d) Bound immuno- 
globulins located in wall of peripheral capillary loops and mesangium in section of same kidney. 
Note the specific absorption of the fluorescence reaction (b and c), and the similar distribution 
of gp69/71 and bound immunoglobulins (a and d).  x  500. 
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these mice have been initiated. The relatedness of these findings to the nuclear 
antigen-antibody system  that  has  been  described  (48, 49)  is  also  yet  to  be 
determined. 
With  B/WF1  mice,  the  gp69/71  was  located  predominantly in  the  wall  of 
peripheral capillary loops, correlating with the severity of capillary damage. In 
contrast, with NZB mice, gp69/71  was mainly deposited in the mesangia, less in 
the peripheral capillary loops. These distribution patterns apparently correlated 
with  the  accelerated  fatal  clinical  course  of lupus-like  glomerulonephritis in 
B/WF~  mice and the slow progressive  course  of chronic glomerulonephritis in 
NZB mice. With AKR/J mice, the detection of gp69/71  and p30 in the glomeruli 
was  enhanced  after  the  elution  of bound  immunoglobulins,  indicating  that 
MuLV antigens in  the  glomeruli of AKR/J mice were  mainly intrinsic to the 
glomeruli,  most  likely  MuLV  antigens  formed  by  mesangial  cells  (50),  and 
suggesting that  locally formed  as  well  as  circulating  and  deposited  (28, 51), 
MuLV antigens may be of importance in the pathogenesis of glomerulonephritis 
in AKR/J mice. 
Summary 
The  use  of monospecific antisera  for  the  analysis by radioimmunoassay and 
immunofluorescence study  of  two  major  viral  proteins,  gp69/71  and  p30  of 
murine  leukemia  virus,  that  could  be  of significance  in  the  pathogenesis  of 
immune  complex  glomerulonephritis  of  mice,  particularly  NZB  and  B/WF1 
hybrid mice, yielded the following conclusions. A remarkably high concentration 
of viral envelope glycoprotein, gp69/71,  was detected in the spleen and serum of 
New Zealand mice (NZB, NZW, B/WF1, and W/BF,); the concentration in the 
spleen was 10-fold greater than that found in AKR mice and 30-fold greater than 
that  present  in  C57BL/6  mice.  The  gp69/71  was  deposited along with bound 
immunoglobutins, apparently as an immune complex, in the diseased kidneys of 
mice, and the glomerular site and extent of deposition of gp69/71  was related to 
the severity of the glomerulonephritis. This study suggests that the pathogenesis 
of immune complex glomerulonephritis (and vasculitis) in mice is related to the 
expression of this specific viral envelope glycoprotein and to the host immune 
response to this protein. 
We  acknowledge our  indebtedness to  Dr.  Leonhard Korngold for helpful advice, Mrs. Phyllis 
Marinaccio for immunohistological  work, Mr. Brent Keller  for technical assistance, Mr. Louis  Dienes 
for photomicrographic  work, and Miss Eva Hochenburger for manuscript preparation. 
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